Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-10-12
2002-09-24
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S245000, C548S311400, C548S364400
Reexamination Certificate
active
06455561
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to novel heterocyclic compounds and to their formulation and use as pharmaceuticals.
BACKGROUND OF THE INVENTION
The modes of action of phosphodiesterases and also tumour necrosis factor (TNF), and the therapeutic utilities of inhibitors thereof, are described in WO-A-97/4433 7 and U.S. Pat. Nos. 5,925,636 and 5,972,936, the contents of which are incorporated herein by reference. These reference describe benzofurans having such activity.
SUMMARY OF THE INVENTION
This invention provides novel compounds having therapeutic utility, in particular for the treatment of disease states associated with proteins which mediate cellular activity, for example by inhibiting TNF and/or PDE IV. According to the invention, the compounds are of formula (i):
wherein R
1
is C
1-3
alkyl optionally substituted with one or more fluorines;
R
2
is CH
2
OCH
3
or 2 or 3-tetrahydrofuranyl,
R
3
is a pyrazole, imidazole or isoxazole group of partial formula (A), (B) or (C)
R
4
is C
1-3
alkyl and
R
5
and R
6
, which may be the same or different, each represents C,
1-3
alkyl, halogen, CF
3
or CN
or a pharmaceutically-acceptable salt thereof
In summary, the compounds of the invention represent a selection within the scope of WO-A-97/44337. The novel compounds have superior in vivo activity.
This invention provides also a method for mediating or inhibiting the enzymatic activity or catalytic activity of PDE IV in a mammal in need thereof and for inhibiting the production of TNF in a mammal in need thereof, which comprises administering to said mammal an effective amount of a compound of Formula (i) or a pharmaceutically-acceptable salt thereof
REFERENCES:
patent: 5925636 (1999-07-01), Dyke et al.
patent: 5972936 (1999-10-01), Dyke et al.
patent: 6121274 (2000-09-01), Ulrich et al.
patent: 9603399 (1996-02-01), None
patent: 9744337 (1997-11-01), None
patent: 9807715 (1998-02-01), None
patent: 9940085 (1999-08-01), None
McGarry, D.G. et al. (1999) “Benzofuran Based PDE4 Inhibitors”Bioorganic & Medicinal Chemistry7:1131-1139.
Dyke Hazel Joan
Lowe Christopher
Montana John Gary
Darwin Discovery Ltd.
McKane Joseph K.
Saliwanchik Lloyd & Saliwanchik
Shameem Golam M. M.
LandOfFree
Heterocyclic compounds and their therapeutic use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic compounds and their therapeutic use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compounds and their therapeutic use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2839929